Leronlimab

Generic Name
Leronlimab
Brand Names
-
Drug Type
Biotech
Chemical Formula
-
CAS Number
674782-26-4
Unique Ingredient Identifier
Y1J4NP8FF0
Background

Leronlimab, or PRO-140, is a human monoclonal antibody developed by CytoDyn. It was first described in the literature in 2001. This antibody binds to CCR5, which may be useful in treating HIV, cancers, and severely ill COVID-19 patients.

Indication

Leronlimab is currently being investigated for the treatment of a number of cancers and HIV.

Recently leronlimab has begun a phase II clinical trial in severely ill COVID-19 patients. Preliminary data shows a reduction in the 'cytokine storm', particularly IL-6, as well as a normalization of the CD4/CD8 T-cell ratio. These results may mitigate immune mediate injury seen in severely ill COVID-19 patients.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News
marketscreener.com
·

CytoDyn Inc. Announces FDA Clearance of its Phase II Oncology Trial

CytoDyn received FDA clearance for its Phase II oncology trial evaluating leronlimab in relapsed/refractory microsatellite stable colorectal cancer. The trial, in partnership with Syneos Health, will kick off in late November 2024, with patient enrollment starting in early 2025.
globenewswire.com
·

CytoDyn Announces FDA Clearance of Its Phase II Oncology Trial

CytoDyn Inc. received FDA clearance for its Phase II oncology trial evaluating leronlimab in relapsed/refractory microsatellite stable colorectal cancer, to be conducted in partnership with Syneos Health, with a trial kickoff in late November 2024 and patient enrollment in early 2025.
cytodyn.com
·

CytoDyn Appoints Dr. Melissa Palmer, M.D., as Lead Consultant in Hepatology

CytoDyn appoints Dr. Melissa Palmer as Lead Consultant in Hepatology to drive research on leronlimab for liver conditions like MASH and fibrosis. Follow-up studies with SMC Laboratories aim to confirm fibrosis reversal observed in previous studies, with results expected in early 2025.
taylorwessing.com
·

Reporting clinical trial results to the market

Two legal cases against NASDAQ-listed biotech executives highlight risks of inaccurate public statements on clinical trials. In RA Capital v ChemoCentryx, investors claim misleading claims on avacopan's trial success. In US v Nader Pourhassan, the former CytoDyn CEO faces fraud charges for allegedly submitting an incomplete BLA for leronlimab.
cytodyn.com
·

CytoDyn Announces Abstract that Highlights Leronlimab's Potential in Mediating ART-Free

CytoDyn's abstract on leronlimab's potential in ART-free viral control in infant rhesus macaques to be presented at the 5th annual HIV Research for Prevention Conference. The study, funded by an NIH grant, highlights promising results of combining early ART with bNAbs and leronlimab, suggesting durable viral control and potential elimination of ongoing ART.
biospace.com
·

CytoDyn Engages Syneos Health as CRO For Its Phase II Oncology Trial

CytoDyn Inc. engages Syneos Health as CRO for Phase II oncology trial evaluating leronlimab in relapsed/refractory micro-satellite stable colorectal cancer. Trial to start screening patients in early 2025.
marketscreener.com
·

CytoDyn Inc. Engages Syneos Health as CRO for Its Phase II Oncology Trial

CytoDyn Inc. engages Syneos Health for Phase II oncology trial evaluating leronlimab in relapsed/refractory micro-satellite stable colorectal cancer. Syneos Health, a leading biopharmaceutical solutions organization, leverages advanced data analytics and AI/ML capabilities to improve outcomes in clinical development and commercialization.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy